Company intelligence / Profile preview
Zila Pharmaceuticals
Phoenix, Arizona, USAzila.com ↗
- Ownership
- Private
- Employees
- ~200
- Development stage
- Other
01
Overview
Zila Pharmaceuticals was a specialty pharmaceutical and medical device company focused on the oral healthcare market. The company developed and marketed a portfolio of products for dental professionals and consumers, most notably the Peridex (chlorhexidine gluconate) oral rinse and the Atridox (doxycycline hyclate) subgingival release system. Zila also pioneered the ViziLite Plus oral cancer screening system, which utilized chemiluminescent light technology to identify abnormal oral lesions. Following its acquisition by Tolmar in 2009, the Zila dental business was subsequently sold to DenMat in 2014, where its core products continue to be distributed.
- Therapeutic areas
- Infectious DiseasesOncology
- Modalities
- Small moleculeDevice
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Zila Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zila Pharmaceuticals.